Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement

Psilocybin and MDMA are moving from largely underground and criminalised use toward authorised medical treatments: Australia's Therapeutic Goods Administration has approved psilocybin and MDMA has advanced toward FDA approval in the US, with other regulators likely to follow. This emergence builds on long Indigenous histories of sacramental use and 20th century scientific research, and it raises questions about whether Western health care systems are ethically prepared to integrate psychedelic medicines in ways that respect their cultural origins and manage the distinctive clinical challenges these agents pose. Mcguire and colleagues convened a multidisciplinary workshop to identify key ethics and policy issues that will arise as psychedelic therapies enter mainstream clinical practice. The meeting aimed to generate consensus recommendations to guide clinicians, regulators, training programmes, payers, and other stakeholders about topics such as reparations and reciprocity, informed consent, professional boundaries (including physical touch), practitioner personal experience, and gatekeeping mechanisms for access and safety.

A 2.5-day workshop held in June 2023 brought together a deliberately diverse group of stakeholders — clinicians, researchers, Indigenous representatives, industry, philanthropy, veterans, retreat facilitators, training programmes, and bioethicists — selected by the meeting organisers (A.L.M., I.G.C., D.S.) for expertise and broad perspective. Participants submitted ethics and policy issues in advance; organisers grouped these into six broad topics (research ethics; managing expectations and informed consent; therapeutic ethics; training, education, and licensure; equity and access; and gatekeeping). At the meeting, presenters with relevant expertise spoke on each topic and facilitated group discussion. At the end of each day facilitators distilled key issues, and on day 3 attendees reviewed and refined a draft summary of recommendations and points of disagreement. Further revisions were made by email. The final report presents consensus recommendations on five primary issues (reparations and reciprocity, equity, and respect; informed consent; professional boundaries and physical touch; personal experience; and gatekeeping) and identifies areas requiring additional research and deliberation. The workshop did not attempt to assess the quality of empirical evidence underlying each issue.

The consensus process produced 20 points of agreement addressing five ethical domains. On reparations, reciprocity, equity, and respect, participants agreed that Western clinical use of psychedelics rests on Indigenous knowledge and practices and that ethical integration requires frameworks centred on reparations, reciprocity, equity, and respect. Open science and data sharing were endorsed as consistent with these values, while acknowledgements of Indigenous sources of knowledge should be required (for example by journals), training programmes should incorporate Indigenous expertise and worldviews, and beneficiaries should pursue appropriate forms of reciprocity. The group identified ongoing debate about intellectual property and benefit sharing and called for further deliberation. Equity obligations were framed broadly to include other marginalised groups harmed by the War on Drugs, with recommendations to increase representation of historically marginalised populations among trainees, research participants, patients, and governance bodies. Regarding informed consent, the consensus emphasised that patients must be counselled about the wide range of possible experiences, including transformative or self-transcendent effects, potential personality changes, the possibility of no response, and risks such as long-term distress, worsening psychiatric symptoms, or cardiovascular effects (noting particular concern for people with a personal or family history of psychosis or those on contraindicated medications). The group highlighted that ‘set and setting’ influence outcomes and that the informed consent process itself may prime expectations; they therefore recommended research — clinical trials that vary informational framing — to understand consent effects. In the interim, practitioners were advised to use general, non-leading descriptions of possible experiences and to consider educational aids (for example videos or simulations) to help prepare patients. On professional boundaries and physical touch, the workshop recognised that psychedelic treatment commonly pairs pharmacology with psychosocial support but that no single care model is yet evidence-based. Physical touch is used in some somatic therapies and Indigenous practices but carries a foreseeable risk of boundary violations, with past abuses cited as a serious concern. The group recommended distinguishing types of supportive touch during consent, ensuring patients can refuse touch even if they change their mind mid-session, preferring a conservative approach that honours prior refusals, and revisiting consent during integration. Supportive touch should be limited to practitioners with specialised training and accompanied by mitigation strategies such as careful vetting, multiple facilitators, or video monitoring. The guidance in this report pertains to competent adults; the authors noted additional protections are required for minors and other at-risk populations. The topic of practitioner personal experience generated recommendations against requiring clinicians to have had psychedelic experiences for certification or licensure. The group observed divergent practices in research trials (some MAPS trial therapists were offered MDMA experiences; psilocybin trials less commonly offered therapist experiences) and noted legal, professional, and medical reasons why clinicians might abstain. They called for research into whether therapist personal experience affects the therapeutic relationship, outcomes, or conflicts of interest, but advised that training programmes should not mandate personal psychedelic experiences as a condition of training. On gatekeeping, participants mapped roles across regulatory agencies, licensure and certification bodies, and payers. Regulators such as the FDA may consider labelling that specifies psychotherapeutic supports and could require REMS-like strategies, though agencies are constrained from regulating the practice of medicine. The DEA’s scheduling decisions were identified as important for research and access. For licensure and certification, the group distinguished prescribing authority from provision of therapeutic support, noting licensure increases accountability but may reduce access and raise costs; existing training costs (reported around US $5,000–$10,000) and the current lack of evidence on optimal training programmes were flagged. Professional societies should define core competencies including professional ethics, respect for Indigenous roots, and attention to structural inequities. Regarding payers, the consensus highlighted reimbursement as a critical determinant of equitable access: the American Medical Association’s new CPT code for “Psychedelic Drug Monitoring Services” (effective January 1, 2024) was mentioned as a positive step, but the assignment of appropriate relative value units and postmarketing evidence will be essential to securing payer coverage and informing reimbursement levels.

The discussion frames the consensus recommendations as preparatory guidance for the anticipated expansion of medically authorised psychedelic therapies. Mcguire and colleagues and the workshop participants argued that clinician education and structured training will be essential to safe implementation and that new policies are required to limit inequities in access. They emphasised perennial bioethical concerns given novel features of these medicines — notably the challenge of obtaining informed consent for potentially transformative experiences, setting appropriate boundaries around supportive touch during altered states, and deciding whether clinician personal experience should play a role in training or practice. Participants positioned their recommendations relative to existing regulatory and social developments: states and countries are already experimenting with different regulatory models, and the postapproval landscape is likely to include tensions between restrictive medical systems and nonmedical or supervised-use frameworks. The group warned that overly restrictive clinical access could push patients toward nonmedical settings. They also anticipated innovation within medical practice, such as telemedicine and off-label uses, which will pose additional ethical and policy questions. The authors acknowledged limits of the consensus process: the workshop did not assess the quality of empirical evidence for each recommendation, and many topics (for example intellectual property and benefit sharing with Indigenous communities) require further deliberation and research. Their overall tone combines optimism about therapeutic potential with a call for careful policy planning and respect for the cultural origins of these medicines.

The authors conclude that the arrival of psychedelic medicines in approved medical practice is a hopeful development for treating mental illness, but they stress the need for clinicians and policymakers to proactively address ethical and policy challenges. They reiterate the importance of respecting the cultural histories and traditions that underlie contemporary uses of these substances while implementing training, regulatory, and equity-focused measures to facilitate safe and just clinical integration.